152 related articles for article (PubMed ID: 26571826)
1. [Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell cancer].
Vladimirova LY; Agieva AA; Engibaryan MA
Vopr Onkol; 2015; 61(4):580-2. PubMed ID: 26571826
[TBL] [Abstract][Full Text] [Related]
2. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
3. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
4. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?
Alorabi M; Shonka NA; Ganti AK
Crit Rev Oncol Hematol; 2016 Mar; 99():170-9. PubMed ID: 26797287
[TBL] [Abstract][Full Text] [Related]
5. Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy.
Lattanzio L; Denaro N; Vivenza D; Varamo C; Strola G; Fortunato M; Chamorey E; Comino A; Monteverde M; Lo Nigro C; Milano G; Merlano M
Cancer Immunol Immunother; 2017 May; 66(5):573-579. PubMed ID: 28197666
[TBL] [Abstract][Full Text] [Related]
6. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
Mehra R; Cohen RB; Burtness BA
Clin Adv Hematol Oncol; 2008 Oct; 6(10):742-50. PubMed ID: 18997665
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
Panikkar RP; Astsaturov I; Langer CJ
Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy: A novel approach in head and neck cancer.
Christy AW; Bojan A
Indian J Dent Res; 2013; 24(2):261-6. PubMed ID: 23965459
[TBL] [Abstract][Full Text] [Related]
9. Head and neck cancer: integrating anti-EGFR treatment with standard therapy.
Kies MS
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S52-9. PubMed ID: 19780246
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
Li JZ; Zheng JW; Zhang ZY
Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
[TBL] [Abstract][Full Text] [Related]
12. [Role of targeted therapy in the treatment of squamous cell head and neck cancer].
Gyergyay F
Magy Onkol; 2007; 51(2):155-7. PubMed ID: 17660872
[TBL] [Abstract][Full Text] [Related]
13. Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy.
Machiels JP; Schmitz S
Curr Opin Oncol; 2011 May; 23(3):241-8. PubMed ID: 21358328
[TBL] [Abstract][Full Text] [Related]
14. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab and the Head and Neck Squamous Cell Cancer.
Concu R; Cordeiro MNDS
Curr Top Med Chem; 2018; 18(3):192-198. PubMed ID: 29332581
[TBL] [Abstract][Full Text] [Related]
16. Manageable early toxicity of cetuximab concurrent with radical radiotherapy for locally advanced head and neck cancer.
Wieczorek A; Hamid A; O'Toole L
Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):496. PubMed ID: 21482459
[No Abstract] [Full Text] [Related]
17. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
[TBL] [Abstract][Full Text] [Related]
19. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
20. Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account?
Herchenhorn D; Ferreira CG
J Clin Oncol; 2011 Apr; 29(10):e283-4; author reply e285-7. PubMed ID: 21300921
[No Abstract] [Full Text] [Related]
[Next] [New Search]
